

# Eculizumab (Soliris)

Provider Order Form rev. 10/30/2023

## PATIENT INFORMATION

Referral Status:  New Referral  Updated Order  Order Renewal

Patient Name:	DOB:	Patient Phone:
Patient Address:	Patient Email:	
Allergies:	<input type="checkbox"/> NKDA	Weight (lbs/kg):      Height (in/cm):
Sex: <input type="checkbox"/> M / <input type="checkbox"/> F	Date of Last Infusion:	Next Due Date:      Preferred Location:

## DIAGNOSIS (Please provide ICD-10 code in space provided)

generalized myasthenia gravis without exacerbation:	Neuromyelitis Optica (NMOSD):
Other:	Description:

## REQUIRED INFORMATION

- For **gMG diagnosis**: Patient is anti-acetylcholine receptor antibody positive (provide documentation)
- For **NMSOD diagnosis**: Patient is anti-aquaporin-4 (AQP4) antibody positive (provide documentation)
- For **gMG diagnosis**: Meningococcal vaccine(s) given on \_\_\_\_\_ date. First Soliris dose may be given at least 2 weeks later unless otherwise specified.

## THERAPY ADMINISTRATION & DOSING (Choose one)

- Administer eculizumab (Soliris) 900mg weekly<sup>1</sup> x4 doses. Dilute with 90 ml 0.9% sodium chloride (*final volume 180 ml*) and infuse over 35 minutes.
- Administer eculizumab (Soliris) 1200mg for the fifth dose one week after the fourth dose (week 5), then every 2 weeks<sup>1</sup> thereafter. Dilute with 120 ml 0.9% sodium chloride (*final volume 240 ml*) and infuse over 35 minutes.
- If infusion is stopped for any reason, total infusion time should not exceed 2 hours
- Monitor patient for hypersensitivity reaction for a period of 60 minutes following each infusion

<sup>1</sup>Recommended dosage time intervals; may adjust +/- 2 days if needed

## ADDITIONAL ORDERS

## PROVIDER INFORMATION

Preferred Contact Name:	Preferred Contact Email:		
Ordering Provider:	Provider NPI:		
Referring Practice Name:	Phone:	Fax:	
Practice Address:	City:	State:	Zip Code:

## REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval)

**Required Documentation:** Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, Disease status, MRI, Flow Cytometry, MG classification, MG-ADL score, EMG results

**Required Labs:** Anti-Ach receptor, Anti-AQP4,

Provider Name (*print*)      Provider Signature      Date

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.